STOCKS TO BUY: We have identified several stocks that can potentially TRIPLE. Learn more!

Deloitte Acquires Fast-Growing Health-Care Data Warehousing And Analytics Firm, Recombinant

NEW YORK, Oct. 29, 2012 /PRNewswire/ -- In a move signaling the growing momentum for using clinical data to transform health care, Deloitte today announced the acquisition of Recombinant Data Corp., a fast-growing provider of data warehousing and clinical intelligence solutions that enable advances in personalized medicine, translational research and health-care performance management.

(Logo:   http://photos.prnewswire.com/prnh/20120803/MM52028LOGO-a)(Logo:   http://photos.prnewswire.com/prnh/20120803/MM52028LOGO-b)

Based in Newton, Mass., Recombinant's ascendency has been driven by opportunities in the health provider, medical research, life sciences and government health markets as they relate to enterprise data integration, population health analytics, clinical genome data assimilation and performance management for accountable care organizations (ACOs). 

Recombinant has enjoyed significant year-over-year growth since it was founded in 2005, defying the economic downturn by emphasizing innovation in helping the health-care industry anticipate a shifting landscape.  Recombinant's business will reside within Deloitte Consulting Innovation under the name " Recombinant by Deloitte."

"Joining forces with Recombinant represents a bold move around innovation that will open new horizons for Deloitte in the life sciences and health-care sectors," said Andrew Vaz, principal and chief innovation officer, Deloitte Consulting LLP.  "It will extend the Deloitte brand into hybrid business models in which world-class services are combined with advanced intellectual property assets."

According to Peter Emerson, chief executive officer of Recombinant, the combination with Deloitte "multiplies in one event our ability to serve clients while opening new opportunities to deliver our products and services more broadly across the marketplace."  Emerson added, "This will allow us to make a greater impact on clients and the direction of health care; Deloitte and Recombinant share the same vision on how the industry is changing, and our combination provides a level of scale that can help reshape the clinical informatics industry."

Jason Girzadas, U.S. managing principal for Deloitte Consulting to the life sciences and health-care industry, added, "This development advances our commitment to provide clients with analytics-based solutions as well as insights that stretch across the spectrum of health sectors. We are excited to have Recombinant as an integral part of our national consulting practice and tightly linked to our life sciences and health-care industry group."

Recombinant's services and products help enable the data management that underpin the formation of value-based payment models that link different health players around patient care.  Recombinant also helps academic medical centers, federal agencies and life sciences companies conduct translational research and analyze phenomic, genomic and bio banking data in pursing personalized and evidence-based medicine.  These solutions can help clients unlock the underlying power of digital data.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
TRY IT FREE
New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,112.19 -206.04 -1.35%
NASDAQ 3,443.20 -38.98 -1.12%
S&P 500 1,628.93 -22.88 -1.39%
US 10 Yr 2.311% +0.129

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs